How GLP-1 Drugs Affect Your Skin: From Ozempic Face to Hair Loss to Possible Psoriasis Benefits

GLP-1 drugs cause a range of skin effects including facial fat loss, hair shedding, and injection reactions, but may also help with wound healing and psoriasis.

Burke, Olivia M et al.·Skin appendage disorders·2025·Moderate EvidenceReview
RPEP-10248ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Review of published literature on dermatologic effects of GLP-1 receptor agonists across diverse patient populations
Participants
Review of published literature on dermatologic effects of GLP-1 receptor agonists across diverse patient populations

What This Study Found

GLP-1 receptor agonists are associated with a range of dermatologic effects — some harmful, some potentially beneficial. On the adverse side: injection-site reactions, immune-mediated responses including hypersensitivity, urticaria, and bullous pemphigoid (a blistering skin condition), facial fat loss dubbed "Ozempic face," and hair loss in the form of telogen effluvium linked to rapid weight loss.

On the potentially positive side, emerging evidence suggests GLP-1 drugs may enhance wound healing and could benefit inflammatory skin conditions like psoriasis. The review highlights that as GLP-1 use expands to millions of patients, dermatologic side effects are becoming an increasingly important clinical consideration.

Key Numbers

How They Did This

Narrative review of published literature on the dermatologic effects of GLP-1 receptor agonists, including case reports, clinical trials, and post-marketing surveillance data on skin-related adverse events and potential therapeutic benefits.

Why This Research Matters

As GLP-1 drugs move from niche diabetes treatments to mainstream weight loss medications used by millions, their skin-related side effects are becoming impossible to ignore. "Ozempic face" has become a cultural phenomenon, and hair loss is a frequently reported concern. At the same time, the anti-inflammatory properties of GLP-1 drugs raise intriguing possibilities for conditions like psoriasis. Dermatologists are increasingly seeing patients on these drugs and need to understand the full spectrum of skin effects.

The Bigger Picture

The dermatologic impact of GLP-1 drugs represents an entirely new area of concern that barely existed five years ago. With tens of millions of prescriptions now written annually, even uncommon skin reactions affect large numbers of people. The emergence of "Ozempic face" has cultural and psychological implications beyond medicine, while the potential anti-inflammatory benefits for conditions like psoriasis could open new therapeutic directions. Dermatology is now an essential part of the GLP-1 conversation.

What This Study Doesn't Tell Us

This is a narrative review, not a systematic review with quantified effect sizes. Many of the reported dermatologic effects come from case reports or small series rather than controlled studies. The causal relationship between GLP-1 drugs and some skin effects (like hair loss) may be confounded by the rapid weight loss itself rather than the drug directly.

Questions This Raises

  • ?Is the hair loss on GLP-1 drugs caused by the rapid weight loss itself or by direct drug effects on hair follicles?
  • ?Could GLP-1 drugs become a recognized treatment option for psoriasis or other inflammatory skin conditions?
  • ?Does the facial fat loss of Ozempic face reverse if patients stop the medication and regain weight?

Trust & Context

Key Stat:
Both risks and benefits for skin GLP-1 drugs cause adverse skin effects like facial fat loss and hair shedding, but emerging evidence also suggests anti-inflammatory benefits for psoriasis and enhanced wound healing.
Evidence Grade:
This is a narrative review summarizing existing literature. It provides a useful clinical overview but relies on case reports and observational data for many of the dermatologic effects described.
Study Age:
Published in 2025, this review captures the current state of knowledge about GLP-1 skin effects as the drugs reach peak prescribing volume.
Original Title:
Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.
Published In:
Skin appendage disorders, 11(5), 416-423 (2025)
Database ID:
RPEP-10248

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is Ozempic face permanent?

"Ozempic face" refers to the gaunt, aged facial appearance caused by rapid fat loss from the face while on GLP-1 drugs. Whether it reverses depends on whether facial fat returns — which may happen if weight is regained. Some patients seek dermal fillers to restore facial volume. The effect is essentially accelerated facial aging from rapid weight loss.

Will I lose my hair on semaglutide?

Some patients experience telogen effluvium — a temporary increase in hair shedding — while on GLP-1 drugs. This is likely caused by the rapid weight loss itself (a known trigger for this type of hair loss) rather than a direct drug effect. The shedding is usually temporary and hair regrows once weight stabilizes, though this can take several months.

Read More on RethinkPeptides

Cite This Study

RPEP-10248·https://rethinkpeptides.com/research/RPEP-10248

APA

Burke, Olivia M; Sa, Brianna; Cespedes, David Alvarez; Tosti, Antonella. (2025). Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.. Skin appendage disorders, 11(5), 416-423. https://doi.org/10.1159/000544023

MLA

Burke, Olivia M, et al. "Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.." Skin appendage disorders, 2025. https://doi.org/10.1159/000544023

RethinkPeptides

RethinkPeptides Research Database. "Dermatologic Implications of Glucagon-Like Peptide-1 Recepto..." RPEP-10248. Retrieved from https://rethinkpeptides.com/research/burke-2025-dermatologic-implications-of-glucagonlike

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.